MBD3L1

Across TCGA pan-cancer cohorts, MBD3L1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MBD3L1 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MBD3L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MBD3L1 expression acts as an unfavorable survival marker.

HNSC, LIHC, and UCEC are the cancer types where MBD3L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.128	0.680	.005	12	view →
LIHC	DFS	Median	All	0.142	0.555	.020	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MBD3L1–HNSC (DFS)

Open the HNSC breakdown →